Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference

Hypertension

Volumn 54, Issue 4, 2009, Pages 707-709

  Wenzel, Philip ^a   Schulz, Eberhard ^a   Münzel, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; CYCLOOXYGENASE 2; CYTOCHROME P450; DRUG METABOLITE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXP 3179; GELATINASE B; INDOMETACIN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE B BETA; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HYPERTENSION; NOTE; PHAGOCYTE; PLEIOTROPY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HUMANS; HYPERTENSION; LOSARTAN; MATRIX METALLOPROTEINASE 9; NADPH OXIDASE; PHAGOCYTES; PROTEIN KINASE C;

EID: 70349672870     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.136218     Document Type: Note

References (9)

1. Meier P, Maillard M, Burnier M. The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:15-30
2. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460 (Pubitemid 47529329)
3. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res. 2005;65:16-27
4. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14-E22
5. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA, MacHarzina R, Brasen JH, Meinertz T, Munzel T. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int. 1999;55: 252-260
6. Li H, Witte K, August M, Brausch I, Godtel-Armbrust U, Habermeier A, Closs EI, Oelze M, Munzel T, Forstermann U. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol. 2006;47:2536-2544
7. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572-2579
8. Zalba G, Fortuno A, Orbe J, San Jose G, Moreno MU, Belzunce M, Rodriguez JA, Beloqui O, Paramo JA, Diez J. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase- 9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:587-593
9. Fortuño A, Bidegain J, Robador PA, Hermida J, López-Sagaseta J, Beloqui O, Diez J, Zalba G. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension. 2009;54: 744-750